Sugi Predict

Sugi Predict / Compounds / SCHEMBL392889

SCHEMBL392889

SCHEMBL392889

NS(=O)(=O)N1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 1.00
▸ CA2 P00918 3/20 1.00
▸ POLB P06746 1/20 0.58
▸ TSHR P16473 4/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ USP2 O75604 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA7 P43166 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CA13 Q8N1Q1 1/20 0.37
▸ GAA P10253 1/20 0.36
▸ FKBP1A P62942 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2017488 1.00 CA1 (1.00) CA1CA2POLBTSHRKMT2A
SCHEMBL2724764 1.00 CA1 (1.00) CA1CA2POLBTSHRKMT2A
SCHEMBL21356989 1.00 CA1 (1.00) CA1CA2POLBTSHRKMT2A
SCHEMBL391423 0.97 — —
SCHEMBL2723676 0.97 — —
Hydrochloric Acid SCHEMBL29819829 0.93 CA1 (0.88) CA1CA2POLBTSHRKMT2A
SCHEMBL1486989 0.90 — —
Carbamic Acid SCHEMBL3668356 0.87 CA1 (0.75) CA1CA2POLBTSHRKMT2A
Piperidine SCHEMBL6170163 0.84 CA2 (0.71) CA1CA2POLBTSHRKMT2A
Carbamic Acid SCHEMBL1269504 0.83 CA1 (0.70) CA1CA2POLBTSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 822 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250018049-A1 COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY NIKANG THERAPEUTICS, INC. 2025-01-16 — — US claimed
EP-3394068-B1 TDO2 INHIBITORS GENENTECH INC (US) 2024-09-11 — — EP claimed
CN-118401505-A Heterocyclic compounds as SHP2 inhibitors, compositions comprising the same, and methods of use thereof 捷思英达控股有限公司 2024-07-26 — — CN claimed
CN-117645567-A Chalcone derivative containing piperidine sulfonamide structure, and preparation method and application thereof 贵州大学 2024-03-05 — — CN claimed
US-20240034731-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. 2024-02-01 — — US claimed
WO-2024020419-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2024-01-25 — — WO claimed
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 — — US claimed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 — — US claimed
CN-110072864-A TDO2 INHIBITORS 基因泰克公司 2019-07-30 — — CN claimed
US-10344031-B2 Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2019-07-09 — — US claimed
EP-1140873-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES Janssen Pharmaceutica N.V. (BE) 2001-10-10 — — EP claimed
EP-1133483-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2001-09-19 — — EP claimed
EP-1133482-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2001-09-19 — — EP claimed
WO-2001010866-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2001-02-15 — — WO claimed
WO-2000037451-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-06-29 — — WO claimed
WO-2000031053-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-06-02 — — WO claimed
WO-2000031054-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-06-02 — — WO claimed
EP-1000040-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-05-17 — — EP claimed
EP-0987265-A1 Interleukin-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-22 — — EP claimed
WO-1999002505-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof HBZ, ZFX, WIZ CA1 4813/4885CA2 3395/4885POLB 981/4885
US-20240034731-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE CCNI, CDKN1A, CDK8 CA1 723/4885CA2 1435/4885POLB 162/4885
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof HBZ, ZFX, WIZ CA1 4813/4885CA2 3395/4885POLB 981/4885
US-20250018049-A1 COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY CDK2, SKP2, CDK5 CA1 4346/4885CA2 4326/4885POLB 776/4885
US-10344031-B2 Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors MUSK, DMPK, PNCK CA1 4699/4885CA2 3771/4885POLB 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.